Navigation Links
Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber
Date:4/17/2008

Hospital will significantly expand its services, treating up to 24 patients

at a time

MILWAUKEE, April 17 /PRNewswire/ -- Aurora St. Luke's Medical Center's new hyperbaric chamber will triple the hospital's capacity to treat patients with hyperbaric oxygen therapy and improve its regional wound care services.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080417/AQTH107)

The 52-foot-long, 66-ton chamber, the second-largest in the U.S. and the largest in Wisconsin, will be able to treat up to 24 patients at one time.

The chamber was installed today after being lifted by a huge crane and placed into the basement of Aurora St. Luke's through a 1,100-square-foot hole.

Hyperbaric chambers are primarily used to help treat difficult wounds, such as diabetic foot ulcers, but also are used for carbon monoxide poisoning and a host of other medical conditions. During hyperbaric treatment, patients breathe 100 percent oxygen in a pressurized chamber. The increased oxygen in the blood stimulates small blood vessel and skin growth and helps fight infection.

"This new chamber will allow us to continue to provide our patients with the most advanced, state-of-the-art technologies available in wound care," said Jeffrey A. Niezgoda, M.D., medical director of Aurora's Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy Program. "Aurora St. Luke's Medical Center has always been a pioneer in the field of hyperbaric medicine. This new chamber will allow us to continue to attract patients from throughout the Midwest."

Hyperbaric treatment can literally save the lives and limbs of patients with wounds that are difficult to treat because of chronic medical conditions such as diabetes and arterial vascular disease, Dr. Niezgoda said.

Jack Simanonok, M.D., another hyperbaric physician in the Aurora program,
'/>"/>

SOURCE Aurora Health Care
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora, Ontario Wal-Mart Store # 5778
2. Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement
3. Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS
4. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results
5. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
6. IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments
7. Heritage Victor Valley Medical Group Celebrates Earth Day
8. Medical Tourism Association Announces Worlds Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008
9. Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells
10. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
11. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...survivors of testicular cancer who were treated wi...de effects, including neurological side effects an...eated with chemotherapy, according to a new study ...e National Cancer Institute . , Marianne Brydy, ...versity Hospital, in Bergen, Norway, and colleague...
(Date:11/25/2009)...lready used to fight rheumatoid arthritis, could h... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dr...nd rheumatoid arthritis now also shows some promis...diabetes. , The drug, rituximab (Rituxan), help...in, even though the disease had destroyed some of ...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/-- MISSIONSkincare ®isp...orSt.Jude.AspartofGNC,sannualSt.Jude ThanksandGivi...kincare,s new SUPER-C(TM)LipBalm willbedonatedto...ytomakea$1,$5or$10donationatcheckoutatoneoftheir5,...than$1millionforSt.Judeduringtheir2009 ThanksandGi...
(Date:11/25/2009)...s behavior problems that can occur in children wit...h a treatment plan that includes medication combin... according to Yale University researchers and thei...issue of the Journal of the American Academy of C...ducted by the National Institute of Mental Health ...
(Date:11/25/2009)... BioSpace.com, the premier resource f...the third edition of the BioForest™ Hotbed C...nglewood, CO (Vocus) November 25, 2009 -- BioSpace...s and information, unveiled the third edition of t... , , , ,This regional campaign is a promotional e...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
...ull House and,Senate poised to vote on the Preside...horization bill, a five-year, $50 billion initiati...rldwide, Congress must address,the critical HIV pr... nearly two million more,people have access to ant...
...LY AGGRESSIVE VACCINATION SCHEDULE TO,COMBAT RISIN...children who,regressed into autism after receiving...vernment health officials may at last be catching ...nference call held earlier in March,bringing toget...
...tinue the habit after initial coil treatment surge...- Smokers with a brain aneurysm who are treated wi...tients to develop another aneurysm, according to a...the groin and then threaded to the affected area o...
...w medications longer, study finds , , FRID...second-generation antipsychotics are no better tha...pisode of schizophrenia, a new study finds. , Howe... we compared newer drugs to older drugs, we found ...
... T. Clark, Chief,Executive Officer and President o...eutical Research and Manufacturers of America (PhR...g. Also elected were AstraZeneca Chief,Executive O...asurer., In addition, PhRMA announced that Takeda...
...n German . , Boxing is possibly less dangerous ... amateurs. However, conclusive statements on the l...ssional boxers such as Muhammad Ali contracted the...il more extensive studies of both amateur and prof...
Other Medicine News:Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Smokers at Increased Risk of Aneurysm Recurrence 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Richard T. Clark Elected PhRMA Board Chairman 2Health News:Richard T. Clark Elected PhRMA Board Chairman 3Health News:Richard T. Clark Elected PhRMA Board Chairman 4Health News:Richard T. Clark Elected PhRMA Board Chairman 5Health News:How dangerous is boxing for the brain? 2
(Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
(Date:11/24/2009)...,, WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNew...heU.S.FoodandDrugAdministration(FDA)hasacceptedfor...mgAricept®(donepezilHClextendedrelease)tablet...se(AD).Thisnewhigherdoseformulationcontains23mgofd...thadeliverysystemthatallowsforgradualreleaseofthed...
(Date:11/24/2009)...,, STAMFORD,Conn.,Nov.24/PRNewswire/--Zargis...E )andaspin-offfromSiemensCorporateResearch(NYSE: ...sfeaturedontheNovember24,2009episodeofCBS, TheEarl...PopularScience magazine,reviewedfivewinningproduct...,, TheEarlyShow isawidely-viewedtelevisionmorn...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 1Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 2Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 1Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 1Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 3Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 4
...INESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMGN) to...e-blind, placebo-controlled Phase 3 study evaluati...tin alfa) for the,treatment of anemia in patients ...adiotherapy ("the 103 study"). Aranesp is not,appr... These,results were presented in an oral session a...
...primary endpoint not met; plausibly,confounded by ...TUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstC...yers Squibb Company today,announced detailed resul... multi-center Phase III trial - comparing ERBITUX(... in patients with,metastatic colorectal cancer (mC...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
Sophia Vest V-654
Gabrielle Vest V-650
Female Mini-VEST, Front Closure, X-Firm
Male Support Brief
Medicine Products: